News

BlockBeats News, April 6th, BlackRock is setting its sights on a segment of the $13.7 trillion U.S. ETF market that has long been dominated by SSGA: tracking the NASDAQ 100 Index. According to a filing submitted to the U.S. Securities and Exchange Commission (SEC) on Monday, the iShares NASDAQ 100 ETF will track this index, with the ticker symbol IQQ. If the fund is launched, IQQ will become one of the few U.S.-listed ETFs specifically tracking the NASDAQ 100 Index, and the first similar product not managed by SSGA. Since the NASDAQ Stock Market introduced the index in 1985, it has been cautious about authorizing its use. Although there are ETF products in the U.S. market that overlay NASDAQ 100 constituent stocks through derivatives, SSGA has almost monopolized the market for pure NASDAQ 100 Index ETFs. This partnership has spawned the $374 billion Invesco QQQ Trust (ticker: QQQ), one of the world's largest ETFs, as well as the $70 billion SSGA NASDAQ 100 ETF (Jinse).

According to official disclosures from Strategy reported by ChainCatcher, Strategy purchased 4,871 BTC last week at an average price of approximately $67,718, with a total expenditure of about $329.9 million.

This agreement marks a significant step for Zivo Bioscience in turning laboratory research results into commercial products, laying a solid foundation for future market expansion. According to the terms of the agreement, Cyanotech will use its advanced microalgae cultivation facilities in Hawaii to provide Zivo Bioscience with large-scale production services that meet current Good Manufacturing Practice (cGMP) standards. Zivolife™, as a specialty algae biomass rich in bioactive components, has broad application prospects in nutritional supplements, functional foods, and animal health sectors. This collaboration not only demonstrates the synergistic effects between both parties in the microalgae technology field, but also highlights Zivo Bioscience's clear path to accelerating product commercialization through strategic partnerships. With production capacity now secured, the company is expected to bring the Zivolife™ product line to market more quickly, providing innovative solutions for the global health industry.